Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05076175 · ClinicalTrials.gov registry record · Phase 2
A Study Investigating Oral Ozanimod (RPC1063) in Pediatric Participants With Moderate to Severe Active Ulcerative Colitis
A Phase 2 study of Colitis, Ulcerative, sponsored by Bristol-Myers Squibb.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 120
- Enrollment target
- 20
- Study locations
NCT05076175: Recruiting Phase 2 study of Colitis, Ulcerative, sponsored by Bristol-Myers Squibb.
NCT05076175 is a Phase 2 study of Colitis, Ulcerative that is actively recruiting participants, run by Bristol-Myers Squibb. The registered enrollment target is 120 participants, below the 401-participant average among 28 other Colitis, Ulcerative trials with a reported enrollment target (70% lower). The trial reports 20 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05076175, a Phase 2 study of Colitis, Ulcerative, is actively recruiting participants, sponsored by Bristol-Myers Squibb.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 120 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the effectiveness and safety of ozanimod (RPC1063) in achieving and maintaining clinical remission. Ozanimod will be administered orally to pediatric participants with moderate to severe active ulcerative colitis (UC) who have had an inadequate response to conventional therapy.
Conditions Studied
Interventions
- DRUG Ozanimod
Study Locations (20)
California
- Local Institution - 0052 - Garden Grove
- Loma Linda University Health System - Loma Linda
- Cedars-Sinai Medical Center - Los Angeles
- Lucile Packard Children's Hospital - Palo Alto
- Local Institution - 0096 - Sacramento
Massachusetts
- Boston Children's Hospital - Boston
- Local Institution - 0042 - Springfield
- University of Massachusetts Chan Medical School - Worcester
Arizona
- Local Institution - 0041 - Phoenix
- University of Arizona - Tucson
Connecticut
- Local Institution - 0007 - Hartford
District of Columbia
- Local Institution - 0064 - Washington D.C.
Florida
- Local Institution - 0075 - Orlando
Georgia
- Local Institution - 0016 - Atlanta
Illinois
- Local Institution - 0101 - Park Ridge
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2022-05-30 |
| Est. Completion | 2031-08-14 |
| Phase | Phase 2 |
What NCT05076175 shows while recruiting
NCT05076175 is an interventional study that assigns participants to a tested intervention. The registered 120 participants enrollment target is mid-sized for trials with a published cap, below the 401-participant average among 28 other Colitis, Ulcerative trials with a reported enrollment target (70% lower).
The record links to 1 condition, with Colitis, Ulcerative appearing as the primary indexed condition, and to 1 intervention - of which Ozanimod is the first listed.
NCT05076175 names 20 study sites across 13 states, led by California, Massachusetts, Arizona.
Frequently Asked Questions
What is clinical trial NCT05076175 about?
NCT05076175 is a clinical study titled "A Study Investigating Oral Ozanimod (RPC1063) in Pediatric Participants With Moderate to Severe Active Ulcerative Colitis". The purpose of this study is to evaluate the effectiveness and safety of ozanimod (RPC1063) in achieving and maintaining clinical remission. Ozanimod will be administered orally to pediatric participants with moderate to severe active ulcerative colitis (UC) who have had an inadequate response to co...
What is the current status of trial NCT05076175?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 120 participants. The study started on 2022-05-30. Estimated completion is 2031-08-14.
What conditions does trial NCT05076175 study?
This clinical trial studies the following conditions: Colitis, Ulcerative.
What interventions are being tested in trial NCT05076175?
The interventions under investigation include: Ozanimod (DRUG).
Who is sponsoring clinical trial NCT05076175?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05076175 being conducted?
This trial has 20 study locations across Arizona, California, Connecticut, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Colitis, Ulcerative
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05076175's enrollment target sits among peer trials
120 21st of 28 higher than 8 of 28 other Colitis, Ulcerative trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Colitis, Ulcerative trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis
RECRUITING · Phase 2
-
Pharmacologic Weight Loss as Adjunct Therapy for Ulcerative Colitis in Obese Patients
RECRUITING · Phase 2
-
A Study to Investigate Efficacy and Safety of SAR441566 in Patients With Ulcerative Colitis
RECRUITING · Phase 2
-
A Study to Evaluate the Long-Term Effect of TEV-48574 in Moderate to Severe Ulcerative Colitis or Crohn's Disease
ACTIVE NOT RECRUITING · Phase 2
-
VTX002 Versus Placebo for the Treatment of Moderately to Severely Active Ulcerative Colitis
ACTIVE NOT RECRUITING · Phase 2
-
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01174108 · 120 participants · Phase 2
Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells
- NCT01627301 · 120 participants · NA
Sympathetic Overactivity in Post-traumatic Stress Disorder
- NCT02025023 · 120 participants · Phase 3
Local 5-Fluorouracil Injection for the Treatment of Chalazia: A Prospective, Comparative Study
- NCT02128906 · 120 participants · Phase 2
Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI